PCN113 PHARMACOECONOMIC ANALYSIS OF CAPECITABINE PLUS OXALIPLATIN (XELOX) VERSUS 5-FLUOROURACIL/LEUCOVORIN PLUS OXALIPLATIN (FOLFOX) IN THE FIRST LINE TREATMENT OF METASTASIS COLORECTAL CANCER IN TAIWAN
Oct 1, 2009, 00:00
10.1016/S1098-3015(10)74364-3
https://www.valueinhealthjournal.com/article/S1098-3015(10)74364-3/fulltext
Title :
PCN113 PHARMACOECONOMIC ANALYSIS OF CAPECITABINE PLUS OXALIPLATIN (XELOX) VERSUS 5-FLUOROURACIL/LEUCOVORIN PLUS OXALIPLATIN (FOLFOX) IN THE FIRST LINE TREATMENT OF METASTASIS COLORECTAL CANCER IN TAIWAN
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)74364-3&doi=10.1016/S1098-3015(10)74364-3
First page :
Section Title :
Open access? :
No
Section Order :
290